Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 3
1978 3
1979 4
1980 4
1981 4
1982 6
1983 8
1984 8
1985 11
1986 3
1987 8
1988 10
1989 11
1990 26
1991 15
1992 8
1993 20
1994 19
1995 24
1996 30
1997 32
1998 38
1999 57
2000 61
2001 59
2002 72
2003 97
2004 84
2005 112
2006 110
2007 122
2008 168
2009 153
2010 178
2011 200
2012 224
2013 209
2014 243
2015 292
2016 306
2017 305
2018 334
2019 376
2020 459
2021 527
2022 481
2023 415
2024 144

Text availability

Article attribute

Article type

Publication date

Search Results

5,469 results

Results by year

Filters applied: . Clear all
Page 1
Pancreatic Cancer: A Review.
Park W, Chawla A, O'Reilly EM. Park W, et al. JAMA. 2021 Sep 7;326(9):851-862. doi: 10.1001/jama.2021.13027. JAMA. 2021. PMID: 34547082 Free PMC article. Review.
IMPORTANCE: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. ...A multidisciplinary management approach is recommended. Localized pancreas cancer includes resec …
IMPORTANCE: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses e …
Pancreatic cancer.
Mizrahi JD, Surana R, Valle JW, Shroff RT. Mizrahi JD, et al. Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0. Lancet. 2020. PMID: 32593337 Review.
Risk factors for developing pancreatic cancer include family history, obesity, type 2 diabetes, and tobacco use. Patients typically present with advanced disease due to lack of or vague symptoms when the cancer is still localised. ...
Risk factors for developing pancreatic cancer include family history, obesity, type 2 diabetes, and tobacco use. Patients typi …
Pancreatic cancer.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Vincent A, et al. Lancet. 2011 Aug 13;378(9791):607-20. doi: 10.1016/S0140-6736(10)62307-0. Epub 2011 May 26. Lancet. 2011. PMID: 21620466 Free PMC article. Review.
Substantial progress has been made in our understanding of the biology of pancreatic cancer, and advances in patients' management have also taken place. ...Unfortunately, 80-85% of patients present with advanced unresectable disease. Furthermore, pa …
Substantial progress has been made in our understanding of the biology of pancreatic cancer, and advances in patients' …
Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results.
Reyngold M, Parikh P, Crane CH. Reyngold M, et al. Radiat Oncol. 2019 Jun 6;14(1):95. doi: 10.1186/s13014-019-1309-x. Radiat Oncol. 2019. PMID: 31171025 Free PMC article. Review.
Standard doses of conventionally fractionated radiation have had minimal to no impact on the survival duration of patients with locally advanced unresectable pancreatic cancer (LAPC). The use of low-dose stereotactic body radiation (SBRT) in 3- to 5-fr …
Standard doses of conventionally fractionated radiation have had minimal to no impact on the survival duration of patients with locally …
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer.
Stoop TF, Theijse RT, Seelen LWF, Groot Koerkamp B, van Eijck CHJ, Wolfgang CL, van Tienhoven G, van Santvoort HC, Molenaar IQ, Wilmink JW, Del Chiaro M, Katz MHG, Hackert T, Besselink MG; International Collaborative Group on Locally Advanced Pancreatic Cancer. Stoop TF, et al. Nat Rev Gastroenterol Hepatol. 2024 Feb;21(2):101-124. doi: 10.1038/s41575-023-00856-2. Epub 2023 Nov 30. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38036745 Review.
Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases with extensive vascular involvement, which can be classified as either bord …
Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for patients with localized pancreatic …
Irreversible electroporation of locally advanced pancreatic cancer.
Kwon W, Thomas A, Kluger MD. Kwon W, et al. Semin Oncol. 2021 Feb;48(1):84-94. doi: 10.1053/j.seminoncol.2021.02.004. Epub 2021 Feb 18. Semin Oncol. 2021. PMID: 33648735 Review.
Locally advanced pancreatic cancer (LAPC) constitutes approximately one-third of all pancreatic cancer, with standard of care inconsistently defined and achieving modest outcomes at best. ...Perhaps most exciting, IRE is thought to have e …
Locally advanced pancreatic cancer (LAPC) constitutes approximately one-third of all pancreatic cancer …
Irreversible Electroporation for Locally Advanced Pancreatic Cancer.
Timmer FEF, Geboers B, Ruarus AH, Schouten EAC, Nieuwenhuizen S, Puijk RS, de Vries JJJ, Meijerink MR, Scheffer HJ. Timmer FEF, et al. Tech Vasc Interv Radiol. 2020 Jun;23(2):100675. doi: 10.1016/j.tvir.2020.100675. Epub 2020 May 25. Tech Vasc Interv Radiol. 2020. PMID: 32591191 Free article. Review.
Several minimally invasive image guided tumor ablation techniques have been added to the treatment spectrum for locally advanced pancreatic cancer (LAPC). Irreversible electroporation (IRE) might have a significant additive value in the management of t …
Several minimally invasive image guided tumor ablation techniques have been added to the treatment spectrum for locally advanced …
Therapeutic developments in pancreatic cancer: current and future perspectives.
Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Neoptolemos JP, et al. Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348. doi: 10.1038/s41575-018-0005-x. Nat Rev Gastroenterol Hepatol. 2018. PMID: 29717230 Review.
The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related mortality in the next decade in Western countries. ...Furthermore …
The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cance …
Pancreatic cancer: An update on diagnosis and management.
Loveday BPT, Lipton L, Thomson BN. Loveday BPT, et al. Aust J Gen Pract. 2019 Dec;48(12):826-831. doi: 10.31128/AJGP-06-19-4957. Aust J Gen Pract. 2019. PMID: 31774983 Free article. Review.
BACKGROUND: Pancreatic cancer has the highest mortality rate among all main cancer types and is the fourth leading cause of cancer death in Australia. ...Pancreatic cancer is categorised as resectable, borderline resectable, locally …
BACKGROUND: Pancreatic cancer has the highest mortality rate among all main cancer types and is the fourth leading caus …
Neoadjuvant therapy for pancreatic cancer.
Gugenheim J, Crovetto A, Petrucciani N. Gugenheim J, et al. Updates Surg. 2022 Feb;74(1):35-42. doi: 10.1007/s13304-021-01186-1. Epub 2021 Oct 9. Updates Surg. 2022. PMID: 34628591 Free PMC article. Review.
Multimodal treatment including surgery and chemotherapy is considered the gold standard treatment of pancreatic cancer by most guidelines. Neoadjuvant therapy (NAT) has been seen as a possible treatment option for resectable, borderline resectable and locally …
Multimodal treatment including surgery and chemotherapy is considered the gold standard treatment of pancreatic cancer by most …
5,469 results